SCHEMBL761668

SCHEMBL761668

C=C1NCCN1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL762780 0.84
SCHEMBL15829242 0.82
SCHEMBL15829241 0.77 CRBN (0.37)
SCHEMBL12176198 0.73
SCHEMBL20014014 0.70
SCHEMBL13971136 0.70
SCHEMBL2971214 0.69
SCHEMBL182943 0.69
SCHEMBL12648247 0.67
SCHEMBL14365968 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295619-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-09-21 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
EP-3652159-B1 SUBSTITUTED THIAZOLE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER DISEASES, AUTOIMMUNE AND NEURODEGENERATIVE CONDITIONS CYTEIR THERAPEUTICS INC (US) 2023-01-18 EP disclosed
WO-2022212720-A1 GENETICALLY MODIFIED HUMAN CELL LINES AND USES THEREOF SIGILON THERAPEUTICS, INC. (US) 2022-10-06 WO disclosed
WO-2022026606-A2 GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF SIGILON THERAPEUTICS, INC. (US) 2022-02-03 WO disclosed
WO-2021102271-A1 MONOCLONAL CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF SIGILON THERAPEUTICS, INC. (US) 2021-05-27 WO disclosed
WO-2020198685-A1 COMPOSITIONS, DEVICES AND METHODS FOR TREATING FABRY DISEASE SIGILON THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed
WO-2019195055-A1 IMPLANTABLE PARTICLES AND RELATED METHODS SIGILON THERAPEUTICS, INC. (US) 2019-10-10 WO disclosed
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-13 US disclosed
US-20110124874-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
US-20110124875-A1 IMINOPYRIDINE DERIVATIVES AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
US-20110034464-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-10 US disclosed
US-20100210762-A1 HETEROCYCLIC COMPOUND, ULTRAVIOLET ABSORBENT AND COMPOSITION CONTAINING THE SAME FUJIFILM CORPORATION (JP) 2010-08-19 US disclosed
US-20100130638-A1 ULTRAVIOLET ABSORBENT COMPOSITION FUJIFILM CORPORATION (JP) 2010-05-27 US disclosed
US-20100112090-A1 NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD (JP) 2010-05-06 US disclosed
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD (JP) 2010-04-08 US disclosed
US-20090270393-A1 Iminopyridine Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
CN-1139998-C Electrically erasable molecular base organic electric bistable film device and its producing technology 复旦大学 2004-02-25 CN disclosed
CN-1352470-A Electrically erasable molecular base organic electric bistable film device and its producing technology UNIV FUDAN (CN) 2002-06-05 CN disclosed